Category: Assay Development and Screening
The screening of cellular pathways for new therapeutics can be advanced more rapidly if primary drug targets can be simultaneously counter-screened for secondary targets, such as for off-target action. Such duoplex measurements have been unavailable in a homogeneous, rapid assay format. Here we describe such capability using the Alpha SureFire® Ultra™ Multiplex detection system.
Incorporating dual CaptSure™ technologies, these assays provide duoplexed measurements of virtually all SureFire Ultra assay targets, where scientists can pick whichever two targets they require to measure on a particular day. Further, each well can measure any two phosphoprotein targets in the assay range. Such pick-and-pack capability and unsurpassed sensitivity provides a new dimension to cellular research and drug discovery efforts.
Setup of a Multiplexed SureFire Ultra assay is a simple process. The currently available Alpha SureFire Ultra assay kits (ALSU kits) are combined with one of the recently released Terbium SureFire Ultra assay kits (TBSU kits). The TBSU kits contain the reagents required for the multiplex assays, including antibodies for a second assay target of choice, and the associated Terbium Acceptor beads.
Michael Crouch– Director Business Development, TGR BioSciences, Thebarton, South Australia, Australia
Director Business Development
Thebarton, South Australia, Australia
Michael Crouch completed his PhD in cellular signaling systems and continued his career studying a variety of receptor-mediated events, including inositol phospholipid turnover, G-protein signaling, and protein kinase pathways. After about 20 years in basic research, Michael moved to the commercial sector, and has been at TGR BioSciences for the last 16 years. During this time he has been involved in the concept, development and commercialisation of TGR's assay technologies and products, and now leads the business development effort of the company.